FindTrial
Sign In

Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation

Effects of Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation in Patients With Hemophilia A and Antibodies to Factor VIII

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00375323
Enrollment
Unknown
Registered
2006-09-12
Start date
Unknown
Completion date
Unknown
Last updated
2007-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A

Keywords

factor VIII inhibitor

Brief summary

The purpose of the study is to compare the effects of recombinant factor VIIa (NovoSeven) on restoring coagulation activation between patients with hemophilia A and antibodies to factor VIII and normal subjects (controls) by use of an in vivo method.

Interventions

DRUGNovoSeven

Sponsors

Medical University of Vienna
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum

Inclusion criteria

* Adult patients with hemophilia A and current antibodies to factor VIII -

Exclusion criteria

* Life-threatening hemorrhage * Severe liver failure * Any other severe co-morbidity (including diabetes mellitus, renal failure, cancer, septicemia, disseminated intravascular coagulation, crush injury) * Exposure to other haemostatic drugs during the previous 7 days * Hypersensitivity to hamster, mouse or bovine proteins * Known or suspected allergy to NovoSeven or any of its components

Countries

Austria

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026